17th Annual Bio Innovation Leaders Summit 2025
12th & 13th February 2025
Raffles Singapore
Efficiency, resilience and innovation.
BILS Leaders Summit 2026
11th & 12th February 2026
Royal Lancaster Hotel
Lancaster Terrace, London
Located with CGTI 2026
New Frontier of Biomanufacturing - designed for precision, sustainability and growth.
A leadership forum uniting up to 200 pioneers across biopharma, MSAT, CMC, supply and strategy - those shaping the future of bioprocess innovation through digitisation, automation and intelligent operations.
Chairman: Uwe Gottschalk
Operating Partner, Keensight Capital · Former CSO, Lonza
2026 BILS and CGTI discussions align with the AIO 2026 Agenda, where AI, machine learning, digitisation and operational intelligence converge with human insight to strengthen connectivity, supply and scalable performance across biomanufacturing, advanced therapies and beyond.
Because without connection, innovation stalls.
BILS 2026 brings together C-suite and senior leaders in manufacturing, operations, process development and digital transformation to define the next frontier of biopharma.
The Imperative
Biomanufacturing cannot evolve without intelligence.
Process needs purpose. Supply needs resilience. Data needs design. BILS exists to transform biomanufacturing into an intelligent, sustainable enterprise where digital systems, automation and analytics define performance at scale.
It connects engineering, innovation and execution to create agile manufacturing capable of meeting global demand with integrity.
It is not a discussion, it is a design for reinvention.
The goal is to accelerate sustainable growth through systems that are digital by design and resilient by nature.
Biomanufacturing defines how innovation becomes impact.
As therapies grow in complexity, the systems that produce them must become smarter and more adaptive.
BILS matters because production is no longer a function - it is a capability.
It brings together leaders in process design, digital manufacturing and supply strategy to build ecosystems that learn, scale and sustain.
Through automation, analytics and collaboration BILS creates visibility across the full value chain - from molecule to market.
It transforms manufacturing into a living system of intelligence and purpose.
The goal is to create a biomanufacturing network built for precision, agility and sustainability.
BILS 2026 and CGTI 2026 share one intelligent foundation that now extends through AIO 2026 - the architecture that connects science, systems and supply.
When biomanufacturing and advanced therapies operate within one ecosystem
innovation moves faster, data flows freely
and scale becomes sustainable.
This integration replaces silos with synergy linking design, automation and digital supply in a single intelligent enterprise.
It creates the visibility and agility required to meet patient and global health needs.
The goal is to shape a biomanufacturing landscape where progress is sustainable, collaboration is systemic and performance becomes shared value.
Our 2026 Gathering is Curated For
Audience
Chief Operating Officers -transformation, scale, operating model
Heads of Manufacturing, MSAT and CMC - process design, tech transfer, validation
Leaders in Data, AI and Automation - digital twins, advanced analytics, manufacturing IT
Quality and Regulatory Executives - QA, QMS, GxP, regulatory strategy
Also Welcome
Chief Data and Technology Officer
Head of Manufacturing IT/OT
VP Supply Chain and Logistics
Head of Cold Chain and Distribution
VP Quality Assurance
VP Regulatory Affairs
Head of Compliance and Release CDMO executives: EVP Operations, Head of Client Programs
Why They Gather
Science moves faster than the systems built to sustain it.
Applied intelligence turns information into infrastructure and links algorithms to execution - AI, automation and digital twins as living systems that learn and improve.
For biopharma it enables real-time oversight, continuous validation and reliability across networks.
For CGT it bridges innovation and access at scale without losing purpose.
Science moves faster than the systems built to sustain it.
SPEAKERS
Judy Chou
President and CEO of AltruBio
Uwe Gottschalk
Operating Partner at Keensight Capital
Nuno Fontes
SVP, Head of Global CMC at WuXi Biologics
BILS 2026 | AIO
The Four Pillars of Intelligent Biomanufacturing
1. Intelligence
From data to insight. From insight to action.
Where real-time analytics, predictive modelling and AI-driven process understanding accelerate decision-making across development, CMC and manufacturing.
Why it matters: Speaks to leaders shaping intelligent operations - turning complex data into scalable strategy and measurable performance.
2. Integration
From silos to systems.
Unifying development, production and supply through connected digital ecosystems that align process, technology and quality.
Why it matters: Reflects the pursuit of digital maturity and cross-functional harmony - essential for organisations building end-to-end visibility across biomanufacturing networks.
3. Infrastructure
Where design, quality and automation converge.
A modernised operational backbone where QMS, GxP and validation meet agility through digital twins, modular platforms and intelligent control.
Why it matters: Captures the transformation of biomanufacturing - blending regulatory precision with design thinking and speed to enable compliant, adaptive systems.
4. Impact
From innovation to implementation.
Where science becomes outcomes that improve lives and sustain progress across global manufacturing and supply networks.
Why it matters: Grounds intelligent operations in real-world value - ensuring innovation reaches patients through reliable, scalable and sustainable execution.
Voices of Influence. Leaders of Impact.
ADVISORY
Leadership that shape the future of biologics manufacturing and guide the next decade of innovation.
INVITED ONLY AUDIENCE
For the few who turn vision into verification and make systems that scale science.
Every room has a purpose. Every connection has a next step.
SUMMIT
INSIGHTS
Our Mission
Our purpose is to create a gathering that empowers and inspires critical decision-making; sparking new opportunities to amplify their impact within the biologics and cell and gene therapy value chain.
We encourage collaboration and innovation, which is why this summit ensures that each participant contributes significantly to advancing the field. It serves as a platform for sharing insights, fostering partnerships and driving forward the next wave of breakthroughs in biologics.
For the patients, we must do better.
Investors and large biopharma companies need to satisfy environmental compliance. We will keynote the progression toward more sustainable bioprocesses, manufacturing and supply methods, amalgamating toward building a sustainable and digitised ecosystem - an emerging frontier of digitisation and industry 4.0.
Closing session by Merck.
Attendee Profile
C-Suite - Directors - Executives
Bioprocess - Manufacturing - IT-Data Integration - Commercial and Business Development - Scientists - Supply Chain - Production - PAT
Focus Area
CGT
Antibody Drugs
Vaccine
Small molecule, conjugates and peptides
Technology or Service Companies
CRO
CDMO
Biologic workflow solutions
Advance Bioprocessing
End to end workflow solutions
Digitising - AI - Data
Automation - Robotics
Filtration - Single use - Bioreactors
Event highlights
Pre Event Innovation Tour - Private Innovation Tour - CXO
Please click to Tour 2024
Evening of day one -Private Networking Dinner
Journey of a CXO
Exclusive closed-door talks from some of the most prominent leaders in the industry who will be talking about their journey, lessons learnt and vision for the future.
Attendance Guide
30% Asian Biopharma
25% International Biopharma
20% CMOs - CDMOS's
15% Academic & Research Institutes
10% Technology & Service Providers
Curated Meetings
Packages have sold out
Guaranteed pre-qualified strategy meetings
Prior contact
Mutual benefit
Conducted by our specialists
Geography
25% Korea & Japan
20% Singapore
20% Indonesia, Thailand, Philippines, Malaysia, India & Australia
15% China, Hong Kong & Taiwan
15% USA
5% UAE
Joshi Venugopal
GM & Head of Europe
Novartis Gene Therapies & Rare Diseases
Dorothee Ambrosius
Former Head of CMC Strategy Biologicals
Boehringer Ingelheim
Warner Biddle
Former Global Head of Commercial
Kite, a Gilead Company
Gwendolyn Binder
President of Science & Technology
Cabaletta Bio
Pierre Caloz
COO
uniQure
Paolo Martini
Former CSO
Moderna
CURRENT SPEAKERS
PREVIOUS SPEAKERS
